https://www.benzinga.com/general/biotech/24/06/39212271/abbvies-immunogen-acquired-elahere-meets-primary-goal-in-mid-stage-study-in-heavily-pretreated-ov
AbbVie's Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated...
Jun 6, 2024 - AbbVie announced Phase 2 PICCOLO trial results for Elahere in heavily pre-treated ovarian cancer patients. The trial achieved a 51.9% objective response rate.
https://www.elahere.com/
ELAHERE is a treatment for FRα+ ovarian cancer
What is ELAHERE? A treatment for people with folate receptor alpha–positive ovarian cancer. Learn more about this targeted therapy.
is atreatment forelahereovariancancer
https://pharma.economictimes.indiatimes.com/tag/abbvie+elahere
Abbvie elahere - Latest abbvie elahere , Information & Updates - Pharma -ETPharma
ETPharma.com brings latest abbvie elahere news, views and updates from all top sources for the Indian Pharma industry.
latest informationabbvieelahereupdatespharma